Introduction

Aging is a complex biological process that heightens the risk of various diseases, including thrombosis.² Thrombosis is the pathological formation of bloodclots in arteries or veins and is a serious and potentially life-threatening condition that disproportionately affects elderly patients.³ As people age, physiological changes, chronic health conditions, and lifestyle factors increase the risk of blood clot formation. 

This article examines:

• Key age-specific risk factors contributing to thrombotic events, hallenges of managing thrombosis in the elderly , 
• The latest treatment advancements to enhance patient care and improve outcomes in geriatric care 

The link between ageing and thrombosis

The incidence of venous thrombosis is strongly age-dependent: it is extremely uncommon (1 in 100,000 per year) in childhood and rises to nearly 1% per year in very old age.³ Ageing affects blood coagulation and fibrinolysis through various mechanisms, including increased oxidative stress, which disrupts the balance between oxidants and antioxidants, which can lead to endothelial dysfuncton. This imbalance leads to functional decline and the accumulation of oxidised proteins, such as fibrinogen.²

Older adults are more susceptible to thrombosis due to several biological and lifestyle-related factors:

• Vascular Ageing: Blood vessels become less flexible (loss of vascular elasticity), leading to endothelial dysfunction and increased clotting risk
• Chronic Health Conditions: Diseases such as hypertension, diabetes, atrial fibrillation, and cancer (malignancy)elevate the risk of blood clot formation
• Reduced Mobility and Sedentary Lifestyle: Decreased physical activity due to ageing, hospitalisation, or mobility limitations contributes to venous stasis and deep vein thrombosis (DVT)
• Polypharmacy and Medication Interactions: Elderly patients often take multiple medications, increasing the risk of drug interactions that can affect bleeding and clotting tendencies

Management Challenges of Thrombosis in Geriatric Patients 

Effectively managing thrombosis in elderly patients requires a careful approach due to the following concerns:

• Balancing Anticoagulation Therapy: Older adults are at greater risk of bleeding complications, necessitating precise dosage adjustments
• Cognitive Decline and Medication Adherence: Memory impairments can lead to missed doses or incorrect use of anticoagulants
• Declining Kidney and Liver Function: Age-related organ deterioration affects drug metabolism, requiring regular monitoring and dosage modifications

Age-related prothrombotic changes are complex, involving heightened platelet activation, endothelial dysfunction, and alterations in coagulation factors and inhibitors.²

Read on for prevention and treatment strategies

Although aging increases thrombosis risk, proactive strategies can significantly improve patient outcomes. Continue reading to explore prevention techniques, the latest treatment advancements, and best practices in elderly thrombosis management…

Thrombosis in elderly patients

Thrombosis occurs when a blood clot forms inside a blood vessel, disrupting normal blood flow. It can manifest as deep vein thrombosis (DVT), pulmonary embolism (PE), or arterial thrombosis, each carrying serious health consequences As people age, physiological changes in the circulatory system increase clotting risk. Key factors include elevated levels of fibrinogen and clotting factors (VIII and IX), without a corresponding rise in anticoagulant proteins, creating a prothrombotic state.¹

The likelihood of developing venous thrombosis rises dramatically with age. While rare in children (occurring in just 1 in 100,000 annually), the incidence approaches 1% per year among the very elderly. This age-dependent pattern reflects cumulative changes to the vascular system, including: 

• Reduced Vascular Elasticity: Increases arterial stiffness and promotes clot formation
• Elevated Clotting Factor Levels: Higher concentrations of clotting proteins contribute to a hypercoagulable state

Deep venous thrombosis risk factors

DVTs can be categorised as provoked or unprovoked. Provoked thromboembolisms are associated with known risk factors, often temporary risk factors like surgery or prolonged immobility., Unprovoked DVTs suggest an underlying tendency to clot. In emergency settings, most DVTs are unprovoked, carrying a 15% recurrence risk within 12 months, compared to 5% for provoked cases. Risk factors can be inherited or acquired, with up to 80% of patients having at least one identifiable risk factor.

Acquired risk factors

• Surgeries, Trauma, and Immobilization: Major orthopaedic and neurovascular surgeries (such as hip and knee replacements) significantly increase the risk of DVTs, especially with prolonged surgical and post-surgical immobilization. Prolonged travel, stroke-related immobility, and trauma are also major contributor
• Prior Thromboembolism: A history of DVT or pulmonary embolism (PE) elevates the likelihood of recurrence. This risk is particularly pronounced in cases of unprovoked DVT or when an underlying genetic predisposition exists
• Malignancy: Cancer patients face a higher risk of clot formation due to tumour size, chemotherapy, and central venous catheters. Some cancers, including pancreatic, ovarian, and lung cancer, have particularly high thrombotic potential.
• Pregnancy: The hypercoagulable state of pregnancy, especially post-partum, increases DVT risk. Additional risk factors, including inherited thrombophilias, obesity, and smoking, further amplify this susceptibility
• Antiphospholipid Antibody Syndrome (APLS): This condition is strongly linked to recurrent DVTs, with 14% of recurrent VTE patients testing positive for APLAs⁵
• Chronic Medical Conditions: Heart failure, chronic kidney disease, inflammatory bowel disease, and autoimmune disorders (such as systemic lupus erythematosus) all contribute to a prothrombotic state through various mechanisms, including chronic inflammation and endothelial dysfunction
• Iatrogenic Factors: Hormonal contraceptives, hormone replacement therapy, corticosteroids, and chemotherapy drugs (e.g., tamoxifen, testosterone) have all been associated with increased DVT risk

Inherited risk factors

The most common inherited thrombophilias are the Factor V Leiden mutation and prothrombin gene mutation, responsible for over 50% of inherited thrombophilia disorders. Other inherited conditions, such as protein C/S deficiency and hyper-homocysteinemia, can also increase thrombosis risk. Patients with multiple inherited or combined inherited-acquired risk factors have a significantly higher risk of clot formation.⁵

Challenges in managing thrombosis in elderly patients

Managing thrombosis in elderly patients presents several challenges. Anticoagulation therapy plays a vital role in preventing clots, with medications like unfractionated or low-molecular-weight heparin and fondaparinux commonly used. However, older adults are at a higher risk of bleeding complications, making it essential to carefully balance anticoagulant use.⁶

Direct oral anticoagulants (DOACs) provide a safer and more predictable alternative to traditional warfarin therapy. Additionally, anticoagulants can interact with medications for hypertension, diabetes, and arthritis, requiring careful monitoring and regular medication reviews to minimise adverse effects. Cognitive decline, such as dementia, further complicates adherence, as memory impairments may lead to missed doses, increasing the risk of clot-related complications. In these cases, involving caregivers and using simplified dosing schedules can improve adherence. 

Furthermore, as many anticoagulants are processed through the liver and kidneys, age-related declines in organ function may cause drug accumulation and toxicity, making regular blood tests essential for optimising dosages.⁷

Effective thrombosis management strategies

Pharmacological treatments

• Direct Oral Anticoagulants (DOACs): Apixaban and rivaroxaban are increasingly preferred due to their predictable pharmacokinetics, fixed dosing regimens, and lower bleeding risk compared to traditional anticoagulants
• Low Molecular Weight Heparins (LMWH): Often used in hospitalised patients at high risk of thrombosis
• Warfarin: Suitable for long-term anticoagulation but requires frequent INR monitoring

Non-pharmacological approaches

• Compression Therapy: Compression stockings help prevent DVT by improving circulation⁴
• Early Mobilisation: Encouraging movement after surgery or during hospitalisation reduces clot risk
• Hydration: Staying well-hydrated prevents blood from thickening, reducing clot formation, particularly important for patients with limited mobility

Lifestyle modifications and prevention

• Regular Physical Activity: Walking, stretching, and low-impact exercises improve circulation, even simple leg movements benefit bedbound patients
• Balanced Diet: A diet rich in omega-3 fatty acids supports vascular health, improves endothelial function and reduces inflammation
• Smoking Cessation and Alcohol Moderation: Eliminating these risk factors lowers the likelihood of thrombotic events

Emerging treatments and future prospects

The future of thrombosis management is becoming increasingly promising, with several groundbreaking developments to transform patient care. One of the most exciting advancements is the creation of new anticoagulants designed with improved safety profiles. These medications aim to minimise the risk of bleeding complications while maintaining their effectiveness in preventing clots, offering patients a safer treatment option.⁸

At the same time, research into genetic and biochemical biomarkers is paving the way for more personalised treatment strategies. By identifying individual risk factors, these biomarkers could enable doctors to tailor therapies that are more effective for each patient, leading to better outcomes.

Additionally, the integration of artificial intelligence (AI) into thrombosis prediction is transforming the way we approach this condition. AI-driven data analysis allows for earlier detection, more accurate risk assessment, and the ability to personalise anticoagulant management.⁹ These advancements hold the potential to not only improve the safety and efficacy of thrombosis treatments but also enhance the overall quality of care for patients, marking a significant step forward in the field.

Summary

Thrombosis presents a significant risk to elderly patients due to age-related vascular changes, chronic health conditions, and reduced mobility. Effective management requires a careful balance between anticoagulation therapy and bleeding risk, along with lifestyle modifications and close medical monitoring. Advances in treatment and personalised medicine continue to enhance patient outcomes. Healthcare professionals must remain vigilant in monitoring at-risk individuals to prevent severe complications.